In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Immunologists from UNIGE have discovered the previously unsuspected anti-tumor potential of CD4 T lymphocytes. An important ...

When it is firmly attached to the CD4 receptor, HIV pulls a second, smaller receptor into its embrace. The second is usually the CCR5 receptor, which juts out of the surface of the T cell, but ...

When gp120 unites to the CD4 receptor, it must also connect to a co-receptor like CXCR4 in order to enter the cell. As a result, CXCR4 antagonists are frequently used in HIV treatment.

Before fusion of the HIV viral envelope and host cell membrane can occur, an HIV glycoprotein complex consisting of glycoproteins gp41 and gp120 must bind with the CD4 receptor on the membrane of ...

Again, we have to understand how HIV attaches. HIV attaches to a host cell through glycoprotein-120, as it is referred to, on the virus, and it attaches to the CD4 receptor of a host cell.

The T-cell co-receptor CD4 is required for T-cell activation, and it may be involved in stabilization of the T-cell receptor and class II major histocompatibility complexes during antigen ...

The moving part is a structure called envelope glycoprotein, and AIDS researchers have been trying to figure it out for years because it is a key part of the virus’ ability to dock on a T-cell ...

Genmab granted Merck Serono worldwide rights to develop and market Humax-CD4, which is used for treatment of T-cell lymphomas, an immune system related cancer form, two years ago.

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial The following represents disclosure information ...

However, blocking activin receptor 1C on CD4+ T cells helps prevent the accumulation of immune-suppressing Tregs in tumors and slows tumor growth. We have identified a new target for anticancer ...